Insights

Q&A: How predictive data analytics and proactive recruiting can improve nurse retention

With predictive data analytics becoming a hot topic in the healthcare industry, many of our clients are asking how analytics can help them with their staffing needs – beyond traditional productivity analysis. One of the opportunities we see is the use of predictive data analytics to develop a proactive recruiting model, which is a proven Read More >

Transitional Care Management Billing: 5 Things You Need to Know

Wanda Pell, Director with Novia Strategies, shares 5 things you need to know about transitional care management billing – a financial remedy for physicians and hospitals to offset the expense of following patients after discharge to ensure a smooth transition and reduce readmissions. Download the full white paper at the bottom of this screen to Read More >

Denial management review team decreases annual write-offs by $650,000

The client This three-hospital system wanted to reduce denials and become a top performer in denial prevention and resolution by combining the expertise of clinical and non-clinical staff. The challenge To create a proactive denial management process that would result in decreased denials, our client needed to address their historical data capture challenges and decentralized Read More >

Improving Pay Practices by Reducing Standby & Callback Expense

The client This five-hospital system wanted to improve pay practices by reducing expense related to standby and callback pay in the procedural departments. The challenge With more than $7.3 million spent annually on standby and callback pay in the procedural departments, our client recognized the opportunity to reduce these expenses while simultaneously improving pay practice Read More >

Battling Extreme Drug Price Increases

Top of mind for nearly every hospital or health system CFO is the roughly 10% annual increase in the cost of pharmaceuticals. Many of these healthcare executives might be surprised to learn that the main reason isn’t due to new novel therapeutics, but rather to older medicines with extraordinary price increases. These drug manufacturers are Read More >